Literature DB >> 11925130

Disease persistence in patients with cervical intraepithelial neoplasia undergoing electrosurgical conization.

Silvano Costa1, Maria De Nuzzo, Fanny E Infante, Benedetta Bonavita, Marica Marinelli, Anna Rubino, Valeria Rambelli, Donatella Santini, Paolo Cristiani, Lauro Bucchi.   

Abstract

OBJECTIVE: Cone margin status has been reported to be the most important predictor of residual disease in patients with cervical intraepithelial neoplasia (CIN) undergoing electrosurgical excisional treatment. The primary aim of this study of patients treated with electrosurgical conization was to evaluate the association of cone margin status and other clinical and pathologic factors with the probability of residual disease.
METHODS: The study population comprised 699 patients with at least one follow-up visit within 12 months of conization. Residual disease was defined as a histology diagnosis of CIN within 3 years of conization. Multivariate associations were evaluated with multiple logistic regression analysis.
RESULTS: Attendance to follow-up was 97% for the second visit and 34% for the third visit. Residual disease was detected in a total of 38 patients (5.4%). The detection rate was 3.3% at the first visit, 2.1% at the second visit, and 0.4% at the third visit. An increased probability of residual disease was associated with a referral Pap smear reported as high-grade squamous intraepithelial neoplasia and carcinoma (odds ratio, 2.9; reference category, low-grade squamous intraepithelial neoplasia). A decreased probability was associated with a squamocolumnar junction entirely visible at the first follow-up visit (odds ratio, 0.2; reference category, squamocolumnar junction not visible). Patient age, time period, lesion size, lesion site, grade of CIN, cone width, cone depth, and margin status had no influence.
CONCLUSIONS: The determinants of residual disease in this study differed from those generally reported so far. Factors associated with effectiveness of electrosurgical treatment of CIN need further research.

Entities:  

Mesh:

Year:  2002        PMID: 11925130     DOI: 10.1006/gyno.2001.6579

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  Relationship between positive margin and residual/recurrence after excision of cervical intraepithelial neoplasia: a systematic review and meta-analysis.

Authors:  Hailing Feng; Hai Chen; Dan Huang; Shengke He; Zhiqian Xue; Zhongjun Pan; Huajun Yu; Yongqun Huang
Journal:  Transl Cancer Res       Date:  2022-06       Impact factor: 0.496

2.  Loop electrosurgical excision procedure combined with cold coagulation for cervical intraepithelial neoplasia and adenocarcinoma in-situ: a feasible treatment with a low risk of residual/recurrent disease.

Authors:  Eun Jung Yang; Nae Ry Kim; Ji Yeon Choi; Wook Youn Kim; Sun Joo Lee
Journal:  Infect Agent Cancer       Date:  2020-10-06       Impact factor: 2.965

3.  HPV-DNA testing for cervical cancer precursors: from evidence to clinical practice.

Authors:  M Origoni; P Cristoforoni; S Costa; L Mariani; P Scirpa; A Lorincz; M Sideri
Journal:  Ecancermedicalscience       Date:  2012-06-18

Review 4.  Performance of HPV DNA testing in the follow-up after treatment of high-grade cervical lesions, adenocarcinoma in situ (AIS) and microinvasive carcinoma.

Authors:  Silvano Costa; Simona Venturoli; Massimo Origoni; Mario Preti; Luciano Mariani; Paolo Cristoforoni; Maria Teresa Sandri
Journal:  Ecancermedicalscience       Date:  2015-04-29

5.  Predictors of recurrence in patients with high-grade cervical intraepithelial neoplasia after cervical conization.

Authors:  Yan Ge; Yongli Liu; Yun Cheng; Yanbo Liu
Journal:  Medicine (Baltimore)       Date:  2021-07-09       Impact factor: 1.817

6.  Predictors of persistent cytologic abnormalities after treatment of cervical intraepithelial neoplasia in Soweto, South Africa: a cohort study in a HIV high prevalence population.

Authors:  Yasmin Adam; Cyril J van Gelderen; Guy de Bruyn; James A McIntyre; Diane A Turton; Neil A Martinson
Journal:  BMC Cancer       Date:  2008-07-25       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.